Researchers in the UK have conducted a study assessing the efficacy of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory syndrome coronavirus 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback